- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response -

- Astellas named Working Mother "100 Best Company" for fifth consecutive year -

If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)

- US Employees Support 16 Local Organizations for Changing Tomorrow Day 2019 -

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -

Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy